India has tightened surveillance on GLP-1 weight-loss drugs to curb misuse, unauthorized sales, and unethical promotion. The ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Researchers at the University of Bristol have identified a specific biological mechanism by which GLP-1 drugs, the same class ...

The World Health Organization (WHO) has finally made its recommendations on using glucagon-like peptide-1 (GLP-1) therapeutics for weight loss, though it remains to be seen whether it changes their ...

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

For the more than 48 million Americans with substance use disorders, including a disproportionate share of veterans, GLP-1 ...

Shalini Arunogiri receives funding from the National Health and Medical Research Council. She has received speaker honoraria from Camurus and Indivior, and advisory board fees from Indivior and Eli ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.